Specific changes of sulfatide levels in individuals with pre‐clinical Alzheimer's disease: an early event in disease pathogenesis
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
To explore the hypothesis that alterations in cellular membrane lipids are present at the stage of pre‐clinical Alzheimer's disease (AD) (i.e., cognitively normal at death, but with AD neuropathology), we performed targeted shotgun lipidomics of lipid extracts from post‐mortem brains of subjects with pre‐clinical AD. We found sulfatide levels were significantly lower in subjects with pre‐clinical AD compared to those without AD neuropathology. We also found that the level of ethanolamine glycerophospholipid was marginally lower at this stage of AD, whereas changes of the ceramide levels were undetectable with the available samples. These results indicate that cellular membrane defects are present at the earliest stages of AD pathogenesis and also suggest that sulfatide loss is among the earliest events of AD development, while alterations in the levels of ethanolamine glycerophospholipid and ceramide occur relatively later in disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · cited 3×
“The cases were assessed using established rating scales and neuropathological diagnostic criteria for AD (Braak and Braak 1991; Mirra et al. 1991; NIA-Reagan Institute 1997; Braak et al. 2006; Montine et al. 2012).”
BackgroundMethodMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
Self-citationInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217 · cited 2×
“…of several trials of disease-modifying therapeutics, including several targeting the amyloid precursor protein (APP) and its cleavage product Ab, have highlighted our incomplete knowledge of both cognitive impairment and the pathogenesis of AD (Mangialasche et al. 2010; Salomone et al. 2012).”
Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Holtzman, D. M., Herz, J., & Bu, G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006312 · Cited by 782
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease
Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661
Han, X., M. Holtzman, D., W. McKeel, D., Kelley, J., & Morris, J. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00997.x · Cited by 626 · cited 10×
“…of sulfatide biosynthesis and degradation in AD subjects, but have identified the tight association of sulfatide metabolism with apoE metabolism depending on the expression levels, turnover rates, and isoforms of apoE (Han et al. 2002, 2003a; Han 2007; Cheng et al. 2010b; Kiebish et al. 2012).”
BackgroundResultSelf-citationBozzali, M. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.6.742 · Cited by 568
White matter changes in mild cognitive impairment and AD: a diffusion tensor imaging study
Medina, D., deToledo-Morrell, L., Urresta, F., Gabrieli, J. D. E., Moseley, M., Fleischman, D., Bennett, D. A., Leurgans, S., Turner, D. A., & Stebbins, G. T. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.03.026 · Cited by 492
Han, X., Rozen, S., Boyle, S. H., Hellegers, C., Cheng, H., Burke, J. R., Welsh-Bohmer, K. A., Doraiswamy, P. M., & Kaddurah-Daouk, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021643 · Cited by 429 · cited 1×
“The levels of these lipids are also changed in plasma or cerebrospinal fluid of patients (Han et al. 2003b, 2011; Goodenowe et al. 2007).”
BackgroundSelf-citationWhite matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI
Zhang, Y., Schuff, N., Du, A.-T., Rosen, H. J., Kramer, J. H., Gorno-Tempini, M. L., Miller, B. L., & Weiner, M. W. (2009) · Brain · doi:10.1093/brain/awp071 · Cited by 356 · cited 2×
“The depletion of sulfatides is tightly associated with Ab pathology (Han 2010) and may be linked to the white matter abnormality in AD (Bozzali et al. 2002; Medina et al. 2006; Xie et al. 2006; Yoshiura et al. 2006; Zhang et al. 2009) since sulfatide is exclusively synthesized in oligodendrocytes, is largely present i…”
BackgroundHan, X. (2005) · Current Alzheimer Research · doi:10.2174/1567205052772786 · Cited by 183
Self-citationHan, X. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04708.x · Cited by 101 · cited 2×
“Our previous mechanistic studies have not found any significant dysregulation of sulfatide biosynthesis and degradation in AD subjects, but have identified the tight association of sulfatide metabolism with apoE metabolism depending on the expression levels, turnover rates, and isoforms of apoE (Han et al. 2002, 2003a…”
BackgroundSelf-citationApolipoprotein E mediates sulfatide depletion in animal models of Alzheimer’s disease
Cheng, H., Zhou, Y., Holtzman, D. M., & Han, X. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.07.020 · Cited by 79 · cited 3×
“Lipids were extracted from individual homogenates after protein assay by a modified Bligh and Dyer technique (Cheng et al. 2010b) in the presence of internal standards.”
BackgroundMethodSelf-citation
Cited by
Yin, F. (2023) · The FEBS Journal · doi:10.1111/febs.16344 · Cited by 441
Biological aging processes underlying cognitive decline and neurodegenerative disease
Gonzales, M. M., Garbarino, V. R., Pollet, E., Palavicini, J. P., Kellogg, D. L., Kraig, E., & Orr, M. E. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158453 · Cited by 367
Wang, M., Wang, C., & Han, X. (2017) · Mass Spectrometry Reviews · doi:10.1002/mas.21492 · Cited by 301
Self-citationShinohara, M., Tachibana, M., Kanekiyo, T., & Bu, G. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075796 · Cited by 297
“For example, the reduction of sulfatide levels by LRP1 deletion (118) was observed in the brains of early stage of AD cases (123).”
BackgroundNovel advances in shotgun lipidomics for biology and medicine
Wang, M., Wang, C., Han, R. H., & Han, X. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.12.002 · Cited by 271
Self-citation
Metadata
- Authors
- Cheng, H., Wang, M., Li, J., Cairns, N. J., & Han, X.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2013-07-30
- Volume
- 127
- Issue
- 6
- Pages
- 733-738
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2012601387
- Cited by
- 103
- References
- 16
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.